Accès gratuit
Med Sci (Paris)
Volume 18, Numéro 12, Décembre 2002
Page(s) 1257 - 1265
Section M/S Revues : Articles de Synthèse
Publié en ligne 15 décembre 2002
  1. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol lowering interventions. Arterioscler Thromb Vasc Biol 1999; 19: 187–95. [Google Scholar]
  2. Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001; 107: 1423–32. [Google Scholar]
  3. John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998; 98: 211–6. [Google Scholar]
  4. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126–31. [Google Scholar]
  5. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711–9. [Google Scholar]
  6. Rueckschloss U, Galle J, Holtz J, et al. Induction of NAD (P) H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 2001; 104: 1767–72. [Google Scholar]
  7. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S. Involvement of rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000; 87: 616–22. [Google Scholar]
  8. Tedgui A, Mallat Z. Athérosclérose et inflammation. Med Sci 2001; 17: 162–9. [Google Scholar]
  9. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CARE) investigators. Circulation 1998; 98: 839–44. [Google Scholar]
  10. Horne BD, Muhlestein JB, Carlquist JF, et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000; 36: 1774–80. [Google Scholar]
  11. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230–5. [Google Scholar]
  12. Ambrosi P, Aillaud MF, Habib G, et al. Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients. Thromb Haemost 2000; 83: 46–8. [Google Scholar]
  13. Juhan-Vague I, Alessi MC. Regulation of fibrinolysis in the development of atherothrombosis: role of adipose tissue. Thromb Haemost 1999; 82: 832–6. [Google Scholar]
  14. Nalbone G, Alessi MC, Juhan-Vague I. Système fibrinolytique, métalloprotéases et pathologie vasculaire. Med Sci 2001; 17: 170–6. [Google Scholar]
  15. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998; 83: 683–90. [Google Scholar]
  16. Lopez S, Peiretti F, Bonardo B, Juhan-Vague I, Nalbone G. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 2000; 152: 359–66. [Google Scholar]
  17. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 1999; 19: 2894–900. [Google Scholar]
  18. Yoshida M, Sawada T, Ishii H, et al. HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol 2001; 21: 1165–71. [Google Scholar]
  19. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leucocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7 : 687–92. [Google Scholar]
  20. Bernot D, Benoliel AM, Peiretti F, et al. Atorvastatin inhibits monocyte adhesion to TNFα-activated human endothelial cells (HUVEC). J Cardiovasc Pharmacol 2003 (sous presse). [Google Scholar]
  21. Wojciak-Stothard B, Williams L, Ridley AJ. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J Cell Biol 1999; 145: 1293–307. [Google Scholar]
  22. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926–33. [Google Scholar]
  23. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001; 104: 249–52. [Google Scholar]
  24. Zhao XQ, Yuan C, Hatsukami TS, et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 2001; 21: 1623–9. [Google Scholar]
  25. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684–91. [Google Scholar]
  26. Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057–64. [Google Scholar]
  27. Baldassarre D, Veglia F, Gobbi C, et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis italian ultrasound study. Atherosclerosis 2000; 151: 575–83. [Google Scholar]
  28. Romano M, Diomede L, Sironi M, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000; 80: 1095–100. [Google Scholar]
  29. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671–8. [Google Scholar]
  30. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276–83. [Google Scholar]
  31. Lopez S, Peiretti F, Bonardo B, et al. Effect of atorvastatin on plasminogen activator inhibitor type-1 synthesis in human monocytes/macrophages. J Cardiovasc Pharmacol 2001; 37: 762–8. [Google Scholar]
  32. Kothe H, Dalhoff K, Rupp J, et al. Hydroxymethylglutaryl coenzyme a reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000; 101: 1760–3. [Google Scholar]
  33. Colli S, Eligini S, Lalli M, et al. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17: 265–72. [Google Scholar]
  34. Ganne F, Vasse M, Beaudeux JL, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes : a possible protective mechanism against atherothrombosis. Thromb Haemost 2000; 84: 680–8. [Google Scholar]
  35. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103: 993–9. [Google Scholar]
  36. Guijarro C, Blanco-Colio LM, Massy ZA, et al. Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney Int 1999; 71 (suppl): S88–91. [Google Scholar]
  37. Laufs U, Marra D, Node K, Liao JK. 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27 (Kip1). J Biol Chem 1999; 274: 21926–31. [Google Scholar]
  38. Degraeve F, Bolla M, Blaie S, et al. Modulation of COX-2 expression by statins in human aortic smooth muscle cells: involvement of geranylgeranylated proteins. J Biol Chem 2001; 276: 46849–55. [Google Scholar]
  39. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001; 98: 10344–9. [Google Scholar]
  40. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103: 2885–90. [Google Scholar]
  41. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001; 108: 399–405. [Google Scholar]
  42. Jones S P, Trocha SD, Lefer DJ. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vasc Biol 2001; 21: 2059–64. [Google Scholar]
  43. Ono A, Freed EO. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 2001; 98: 13925–30. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.